e-learning
resources
Milan 2017
Sunday, 10.09.2017
Bronchial asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma
N. Gunsoy (London, United Kingdom)
Source:
International Congress 2017 – Bronchial asthma management
Session:
Bronchial asthma management
Session type:
Thematic Poster
Number:
654
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Gunsoy (London, United Kingdom). Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma. 654
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Mepolizumab improves activity limitation in severe eosinophilic asthma
Source: International Congress 2017 – Notable abstracts in asthma
Year: 2017
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma
Source: International Congress 2017 – Management of asthma in different situations
Year: 2017
Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Year: 2021
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Mepolizumab improves small airway function in severe eosinophilic asthma
Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions
Year: 2018
Are a degree of asthma therapy related to asthma control impairment?
Source: Eur Respir J 2003; 22: Suppl. 45, 370s
Year: 2003
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Daily physical activity and lung function decline in adult-onset asthma
Source: International Congress 2017 – Respiratory and exercise physiology
Year: 2017
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Both moderate and severe exacerbations accelerate physical activity decline in COPD patients
Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept